INFO & CONTACTS:  +39 02 2390 1

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INAVOLISIB COMBINED WITH A CDK4/6 INHIBITOR AND LETROZOLE VERSUS PLACEBO COMBINED WITH A CDK4/6 INHIBITOR AND LETROZOLE IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER K4/6 E LETROZOLO RISPETTO A PLACEBO IN COMPOSTA CON UN INIBITORE DI CDK4/6 E LETROZOLO IN PAZIENTI CON CARCINOMA MAMMARIO AVANZATO ENDOCRINO-SENSITIVO, CON MUTAZIONE DEL GENE PIK3CA, POSITIVO AI RECETTORI ORMONALI E HER2-NEGATIVO

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Bianchi Giulia Valeria

Main Facility: Oncologia Medica 1

Drug: Arm A: inavolisib + letrozolo + palbociclib o ribociclib
Arm B: placebo + letrozolo + palbociclib o ribociclib

Pathologies: Breast cancer

ClinicalTrials.gov: Read more about clinical trials

A Phase III, multicenter, randomized, 1:1, double-blind, placebo-controlled study in patients with hormone-sensitive, PIK3CA-mutated, HR+, HER2-metastatic breast cancer. The study design includes two treatment arms: (ARM A, experimental arm: treated with inavolisib + letrozole + palbociclib or ribociclib – palbociclib or abemaciclib when ribociclib is not approved; ARM B, control arm: placebo + letrozole + palbociclib or ribociclib – palbociclib or abemaciclib when ribociclib is not approved).

Last update: 12/05/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe